TWI896547B - 用於治療cns病症之組合物及方法 - Google Patents

用於治療cns病症之組合物及方法

Info

Publication number
TWI896547B
TWI896547B TW109121938A TW109121938A TWI896547B TW I896547 B TWI896547 B TW I896547B TW 109121938 A TW109121938 A TW 109121938A TW 109121938 A TW109121938 A TW 109121938A TW I896547 B TWI896547 B TW I896547B
Authority
TW
Taiwan
Prior art keywords
compound
substituted
unsubstituted
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
TW109121938A
Other languages
English (en)
Chinese (zh)
Other versions
TW202114700A (zh
Inventor
法藍西司科 G 薩突羅
佩拉杜 馬利亞 耶穌 巴蘭可
馬歇爾 理 莫寧斯塔爾
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW202114700A publication Critical patent/TW202114700A/zh
Application granted granted Critical
Publication of TWI896547B publication Critical patent/TWI896547B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW109121938A 2019-06-27 2020-06-29 用於治療cns病症之組合物及方法 TWI896547B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867618P 2019-06-27 2019-06-27
US62/867,618 2019-06-27

Publications (2)

Publication Number Publication Date
TW202114700A TW202114700A (zh) 2021-04-16
TWI896547B true TWI896547B (zh) 2025-09-11

Family

ID=71728947

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109121938A TWI896547B (zh) 2019-06-27 2020-06-29 用於治療cns病症之組合物及方法

Country Status (13)

Country Link
US (1) US12552829B2 (https=)
EP (1) EP3990469A1 (https=)
JP (2) JP7787635B2 (https=)
KR (1) KR20220038680A (https=)
CN (1) CN114391019A (https=)
AR (1) AR119305A1 (https=)
AU (1) AU2020302748A1 (https=)
BR (1) BR112021026462A2 (https=)
CA (1) CA3143509A1 (https=)
IL (1) IL289172A (https=)
MX (3) MX2021015942A (https=)
TW (1) TWI896547B (https=)
WO (1) WO2020264509A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
JP7787635B2 (ja) * 2019-06-27 2025-12-17 セージ セラピューティクス， エルエルシー Ｃｎｓ障害を治療するための組成物及び方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105822A2 (en) * 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
WO2009142594A1 (en) * 2008-05-20 2009-11-26 Umecrine Ab The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders
WO2014169833A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
CN107936076A (zh) * 2011-09-08 2018-04-20 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969M (fr) 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4060295A (en) 1976-03-15 1977-11-29 Molex Incorporated Zero insertion force printed circuit board edge connector assembly
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
FI972202L (fi) 1994-11-23 1997-07-17 Cocensys Inc Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
HRP20201126T1 (hr) 2014-05-29 2020-12-11 Sage Therapeutics, Inc. Neuroaktivni steroidi, njihovi pripravci i uporabe
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2017049044A1 (en) 2015-09-16 2017-03-23 Bartolucci Giampiero Ursodeoxycholic acid and brain disorders
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
US20190233465A1 (en) * 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
EP3641779B1 (en) * 2017-06-23 2024-02-28 The Board of Trustees of the University of Illinois Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
WO2019041078A1 (en) 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
CN111741965B (zh) 2017-12-22 2024-06-25 萨奇治疗股份有限公司 治疗中枢神经系统疾病的组合物和方法
CN114656514B (zh) 2018-02-11 2024-05-14 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
IL283629B2 (en) * 2018-12-05 2026-03-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
CN116589521B (zh) 2019-01-08 2025-07-11 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
WO2020210117A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
WO2020210116A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
US20230257415A1 (en) 2019-06-27 2023-08-17 Sage Therapeutics, Inc. Compounds for treating cns disorders
JP7787635B2 (ja) 2019-06-27 2025-12-17 セージ セラピューティクス， エルエルシー Ｃｎｓ障害を治療するための組成物及び方法
AU2020304673A1 (en) 2019-06-27 2022-01-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2022115381A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Onc. Compositions and methods for treating cns disorders cross reference to related application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105822A2 (en) * 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
WO2009142594A1 (en) * 2008-05-20 2009-11-26 Umecrine Ab The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders
CN107936076A (zh) * 2011-09-08 2018-04-20 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2014169833A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof

Also Published As

Publication number Publication date
MX2024009926A (es) 2024-08-22
US20220380405A1 (en) 2022-12-01
MX2021015942A (es) 2022-04-18
CA3143509A1 (en) 2020-12-30
TW202114700A (zh) 2021-04-16
BR112021026462A2 (pt) 2022-03-15
AU2020302748A1 (en) 2022-01-06
KR20220038680A (ko) 2022-03-29
WO2020264509A1 (en) 2020-12-30
MX2024009925A (es) 2024-08-22
JP7787635B2 (ja) 2025-12-17
CN114391019A (zh) 2022-04-22
US12552829B2 (en) 2026-02-17
JP2022538299A (ja) 2022-09-01
EP3990469A1 (en) 2022-05-04
US20230303616A9 (en) 2023-09-28
JP2025060984A (ja) 2025-04-10
AR119305A1 (es) 2021-12-09
IL289172A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
TWI896548B (zh) 用於治療cns病症之組合物及方法
TWI896547B (zh) 用於治療cns病症之組合物及方法
TWI864010B (zh) 神經活性類固醇及其組合物
JP7754725B2 (ja) Ｃｎｓ障害を治療するための組成物及び方法
JP7817214B2 (ja) ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
TWI892697B (zh) 神經活性類固醇及其組合物
TWI886813B (zh) 神經活性類固醇及其使用方法
CN115768781A (zh) 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物
KR20230124916A (ko) Cns 장애를 치료하기 위한 조성물 및 방법
BR122025013998A2 (pt) Compostos ou seus sais farmaceuticamente aceitáveis, composição farmacêutica e usos relacionados
BR122025013997A2 (pt) Compostos ou seus sais farmaceuticamente aceitáveis, composição farmacêutica e usos relacionados